LGND vs. HALO, RGEN, MDGL, IONS, ALKS, FOLD, BCRX, DVAX, MNKD, and CLDX
Should you be buying Ligand Pharmaceuticals stock or one of its competitors? The main competitors of Ligand Pharmaceuticals include Halozyme Therapeutics (HALO), Repligen (RGEN), Madrigal Pharmaceuticals (MDGL), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Amicus Therapeutics (FOLD), BioCryst Pharmaceuticals (BCRX), Dynavax Technologies (DVAX), MannKind (MNKD), and Celldex Therapeutics (CLDX). These companies are all part of the "biotechnology" industry.
Ligand Pharmaceuticals vs.
Halozyme Therapeutics (NASDAQ:HALO) and Ligand Pharmaceuticals (NASDAQ:LGND) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership, community ranking and risk.
Halozyme Therapeutics has a net margin of 43.74% compared to Ligand Pharmaceuticals' net margin of 29.68%. Halozyme Therapeutics' return on equity of 157.78% beat Ligand Pharmaceuticals' return on equity.
Halozyme Therapeutics currently has a consensus target price of $62.89, suggesting a potential upside of 6.14%. Ligand Pharmaceuticals has a consensus target price of $146.43, suggesting a potential upside of 34.90%. Given Ligand Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Ligand Pharmaceuticals is more favorable than Halozyme Therapeutics.
Halozyme Therapeutics has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500. Comparatively, Ligand Pharmaceuticals has a beta of 1.07, indicating that its share price is 7% more volatile than the S&P 500.
Ligand Pharmaceuticals received 25 more outperform votes than Halozyme Therapeutics when rated by MarketBeat users. Likewise, 70.45% of users gave Ligand Pharmaceuticals an outperform vote while only 69.47% of users gave Halozyme Therapeutics an outperform vote.
In the previous week, Halozyme Therapeutics had 13 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 23 mentions for Halozyme Therapeutics and 10 mentions for Ligand Pharmaceuticals. Halozyme Therapeutics' average media sentiment score of 0.92 beat Ligand Pharmaceuticals' score of 0.84 indicating that Halozyme Therapeutics is being referred to more favorably in the media.
97.8% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. 2.9% of Halozyme Therapeutics shares are owned by insiders. Comparatively, 5.9% of Ligand Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Halozyme Therapeutics has higher revenue and earnings than Ligand Pharmaceuticals. Ligand Pharmaceuticals is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Halozyme Therapeutics beats Ligand Pharmaceuticals on 10 of the 18 factors compared between the two stocks.
Get Ligand Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for LGND and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ligand Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:LGND) was last updated on 4/25/2025 by MarketBeat.com Staff
Buy LGND Stock Free LGND Stock Alerts